Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Study finds humans were making fire 400,000 years ago, far earlier than once thought - 2Ukraine apologizes to Finland for crashed drones
- 3Palestinians protest against Israel's new death penalty law
- 4Emergency services search for five people last seen in missing Jeep
- 5What were the little white pills found in Tiger Woods's pocket at the scene of his crash? What to know about hydrocodone.
- Higher cost, worse coverage: Affordable Care Act enrollees say expiring subsidies will hit them hard
- Merz says army could be involved in mine-clearing from Hormuz
- Energy agency chief warns of 'black April' for oil supplies
- Strength training is crucial after menopause. How to make the most of your workouts
- Plane Passenger Allegedly Includes ‘Bomb Threat’ in Hotspot Network Name, Forces Flight to Make Emergency Landing
- What's your biological age? Experts explain the benefits and risks of at-home tests
- The most effective method to Pick the Right Teeth Substitution Choice for You
- The Forgotten BMW Coupe That Turned a 5 Series Into Something Far More Exotic
- Arctic sea ice hits lowest winter level as heat records are shattered worldwide
